17 results about "Hepatic stellate cell" patented technology

This invention discloses a method for preparing a co-loaded dual-gene targeted delivery system and its application, involving the construction and preparation of a dual-gene (pHNF4α, pFOXA3) delivery system. This delivery system can target myofibroblasts (MFs) and activated hepatic stellate cells (aHSCs) and can be used for gene therapy of liver fibrosis. This invention synthesizes the targeting carrier material PEI. 25K -PEG 2K -pPB, through electrostatic adsorption, combines with pHNF4α and pFOXA3 to form a co-loaded dual-gene targeted delivery system, F4α / A3@PP-pPB. This delivery system, through the targeting group pPB, binds to MFs (metacellular matrix cells) that lead to excessive accumulation of extracellular matrix in fibrotic livers and to PDGFR (polydimethylformamide) highly expressed on the surface of aHSCs. On the one hand, it inhibits the activation of aHSCs; on the other hand, it transdifferentiates MFs into hepatocyte-like cells (iHep). These two modes, while combating liver fibrosis, can also achieve a certain degree of liver function reconstruction through transdifferentiated iHep cells, providing new ideas and methods for the effective treatment of liver fibrosis.

This invention discloses a method for constructing carrier-free NADH nanoparticles to restore the function of aging hepatocytes, the product, and its applications, belonging to the pharmaceutical field. The method includes preparing carrier-free nano-coordination polymer NADH-Gd using a reverse microemulsion method, followed by a two-step lipid modification process: first, DOPA modification, then DPPC, cholesterol, and DSPE-PEG. 5k NADH-PEG was synthesized by modification, with DSPE-PEG added during the modification process. 5k NADH-Gal is ultimately synthesized from NADH-Gal. NADH-Gal exhibits excellent hepatocyte targeting and can replenish NAD+ in senescent hepatocytes in the MASH environment. + The content is increased by adjusting... Aldh18a1 The expression of [a specific substance] regulates proline metabolism. Improved proline metabolism can restore mitochondrial function by promoting mitophagy and mitochondrial biosynthesis, thereby alleviating hepatocyte aging. Simultaneously, it reduces monocyte recruitment and hepatic stellate cells (HSCs), ultimately providing an effective treatment for MASH. This invention provides a novel strategy for the treatment of MASH.

This invention belongs to the field of medicine, specifically disclosing a drug-loaded biomimetic nanodecoy based on genetic engineering, its preparation method, and its application. The drug-loaded biomimetic nanodecoy of this invention comprises CCR2-overexpressing nanovesicles, and the hydrophobic regions of the nanovesicles are loaded with curcumin. This invention also provides a method for preparing the drug-loaded biomimetic nanodecoy based on genetic engineering and its application. The overexpressed CCR2 is used to adsorb excess CCL2 to inhibit the binding of macrophages to CCL2, preventing macrophage chemotaxis and subsequent TGF-β production. This inhibits the activation of hepatic stellate cells by removing pro-fibrotic mediators upstream; simultaneously, curcumin is released to block the downstream TGF-β / Smad signaling pathway, thereby inhibiting the activation of hepatic stellate cells.

This invention belongs to the field of biomedical technology and discloses the use of catalpol and mesenchymal stem cells in the preparation of drugs for treating liver fibrosis, wherein the concentration of catalpol is 50–200 μM and the concentration of exosomes is 20–50 μg / mL. Simultaneously, this invention constructs a spatially resolved liver fibrosis chip model based on GelMA hydrogel, integrating Kupffer-like cells, hepatic stellate cells, hepatic parenchymal cells, and endothelial cells through a layered sequential seeding strategy, achieving high-precision biomimicry of the liver fibrosis microenvironment. In vitro chip and in vivo animal experiments confirmed that this combined approach can significantly inhibit the expression of collagen synthesis-related genes, improve liver function indicators, and effectively reduce collagen deposition; its anti-fibrotic efficacy is significantly better than the simple superposition of the effects of single components, exhibiting a clear synergistic effect. This invention provides a novel synergistic drug strategy and a highly biomimetic in vitro evaluation platform for the treatment of liver fibrosis.

The application discloses application of a combination of lyophilized powder of Haemadipsa integrifascialis and bear gall powder in preparation of a medicine for treating liver injury, and belongs to the technical field of medicines. The application proves through in-vitro HepG2 and HSC-T6 cell experiments and in-vivo CCl4-induced mouse liver injury models that the combination of the lyophilized powder of Haemadipsa integrifascialis and the bear gall powder can significantly improve the survival rate of injured liver cells, inhibit the activation and fibrosis of hepatic stellate cells, reduce the level of inflammatory factors, improve the antioxidant capacity, reduce the pathological injury of liver tissues, and the synergistic effect is significantly better than that of single medicine, and the safety is good. The application provides a new medicine combination and experimental basis for developing a new liver-protecting and anti-liver fibrosis medicine, and has important clinical application and medicine development values.

This invention discloses the application of primrosein in the preparation of drugs for the treatment of liver fibrosis. The chemical name of primrosein is 2-methoxy-6-pentyl-1,4-benzoquinone, and its molecular formula is C2. 12 O3H 16 Cellular experiments showed that primrosein reduced the proliferative activity of hepatic stellate cells but did not increase the release of lactate dehydrogenase from hepatic stellate cells, and had no significant inhibitory effect on hepatocyte proliferation. Animal experiments showed that primrosein reduced serum levels of markers in carbon tetrachloride-induced liver fibrosis model mice, decreased collagen fiber content in their liver tissue, and inhibited the expression of hepatic stellate cell activation markers, demonstrating excellent anti-liver fibrosis effects. This indicates that primrosein can be used to prepare effective drugs for the treatment of liver fibrosis.

The present invention relates to a three-dimensional (3D) co-culture system that mimics the MASLD microenvironment and is used to investigate its effects on hepatocellular carcinoma (HCC). The system comprises hepatic stellate cells embedded in a collagen matrix and HCC cells cultured in a metabolic medium that simulates MASLD conditions. This model enables the investigation of the molecular mechanisms of HCC under laboratory conditions and can be used to identify new therapeutic targets.

This invention provides the use of terazosin or its pharmaceutically acceptable salts in the preparation of medicaments for the prevention and / or treatment of liver fibrosis, relating to the field of biomedical technology. This invention is the first to discover that terazosin or its pharmaceutically acceptable salts can be used to prevent and treat liver fibrosis. It reveals that terazosin or its pharmaceutically acceptable salts can improve the degree of liver fibrosis by improving liver function, reducing the content of α-SMA (a marker of activated hepatic stellate cells) in liver tissue, reducing the content of Col1a1 in liver tissue, and reducing collagen deposition in liver tissue. Furthermore, the liver-targeted sustained-release drug provided by this invention can reduce the peak plasma concentration of terazosin and prolong its plasma half-life, achieving therapeutic effects equivalent to multiple low-dose injections of terazosin, and has broad application prospects.

Provided herein are isolated D-peptides having one or more D-amino acids, capable of affecting the neuroligin-4 (NLGN4)-neurexin 1β (Nrx1β) protein-protein interaction, wherein the D-peptide has improved human serum stability, enhanced ability to reduce activation of Hepatic Stellate Cells (HSCs) and / or attenuate their proliferation. Further provided are compositions including such peptides and uses thereof for treating and / or attenuating liver-related conditions.

This invention discloses a pharmaceutical composition with preventive or therapeutic effects on liver injury. The pharmaceutical composition consists of turmeric dione and atractylodes lactone II. Through the synergistic effect of turmeric dione and atractylodes lactone II, it is used to treat liver injury caused by various reasons. Cell experiments show that this invention can effectively inhibit the proliferation activity of hepatic stellate cells (LX-2 cells) and inhibit the phosphorylation activation of the PI3K / AKT / mTOR pathway. Animal experiments show that this invention can improve liver function indicators and liver tissue pathological damage in animals with liver injury, regulate blood rheological indicators and related factor levels, and has broad application prospects. The preparation method and application of this invention are also disclosed.

The application discloses application of protosappanin A in preparation of a medicine for treating liver fibrosis, relates to the technical field of biological medicine, and is used for reducing liver fibrosis by targeting CHEK1-mediated proliferation of hepatic stellate cells; the protosappanin A is used for reducing inflammation infiltration, necrosis and collagen deposition of the liver in the liver fibrosis; the medicine comprises protosappanin A and pharmaceutically acceptable adjuvants; the medicine is used for inhibiting activation and / or proliferation of hepatic stellate cells; the medicine is used for reducing liver fibrosis by down-regulating expression levels of CHEK1; a medicine composition for treating liver fibrosis comprises an effective amount of protosappanin A and pharmaceutically acceptable adjuvants; the application discloses a new use of protosappanin A (PrA) in preparation of an anti-liver fibrosis medicine; in-vivo and in-vitro experiments prove that PrA can significantly reduce serum transaminase (ALT, AST) levels, and reduce inflammation infiltration, necrosis and collagen deposition of the liver.

The application discloses a protein degrading agent for targeted degradation of TGFBR2 on the surface of hepatic stellate cells, and a preparation method and application thereof. The protein degrading agent is constructed by coupling TGFBR2 aptamer on the surface of hepatic stellate cell membrane. The preparation method comprises extraction of hepatic stellate cell membrane, modification of TGFBR2 aptamer and coupling on the surface of hepatic stellate cell membrane. The obtained protein degrading agent can specifically recognize TGFBR2 on the surface of activated hepatic stellate cells and promote degradation of the TGFBR2, thereby reducing expression of alpha-SMA and COL1A1, weakening activation of hepatic stellate cells and inhibiting extracellular matrix deposition. The protein degrading agent has good targeting and anti-hepatic fibrosis effects, and can be used for preparing a medicine for treating hepatic fibrosis.

This invention discloses a GKW-TK-Chr conjugate targeting activated hepatic stellate cells, its preparation method, and its application, relating to the field of biomedical technology. The method for preparing this GKW-TK-Chr conjugate, formed by coupling juglansin to the targeting peptide GKWLEQYSRNVP via a thioglycolic acid bond, includes the following steps: S1, synthesizing the intermediate TK-Chr; S2, synthesizing the compound GKW-TK-Chr: combining the intermediate TK-Chr with the peptide... GKWLEQYSRNVP reacts in the presence of a condensing agent to obtain a GKW-TK-Chr conjugate; the GKW-TK-Chr conjugate is used in the preparation of drugs for the prevention and / or treatment of liver fibrosis; the compound GKW-TK-Chr is formed by conjugating apigenin with the targeting peptide GKWLEQYSRNVP via a thioglycolic acid bond, and this conjugate is used in the preparation of drugs for the prevention and / or treatment of liver fibrosis. The conjugate of the present invention can achieve active targeted delivery to activated hepatic stellate cells, thereby improving the therapeutic effect of drugs for liver fibrosis.

To provide a method for preparing quiescent hepatic stellate cells by inducing differentiation of pluripotent stem cells, and to provide a method for screening drugs involved in the activation of quiescent hepatic stellate cells.SOLUTION: According to the present invention, there is provided a method for preparing quiescent hepatic stellate cells, which includes a step of inducing differentiation of iPS cells and isolating quiescent hepatic stellate cells using an NGFR-positive phenotype as an indicator. In addition, there is provided a screening method for selecting a candidate substance for use in a drug for treating or preventing liver disease accompanied by fibrosis based on the expression level of a gene marker that is specifically expressed in activated hepatic stellate cells by introducing a reporter gene into the quiescent hepatic stellate cells.SELECTED DRAWING: Figure 1

The present invention relates to a composition for preventing, ameliorating, or treating kidney and liver diseases, comprising a complex (NEPROBIN) of Ganoderma lucidum extract and Robinia pseudoacacia flower extract as an active ingredient. The complex provided from the present invention exhibits excellent effects in preventing kidney damage, maintaining kidney function, and regenerating kidney tissue by means of inhibition of NO production, reduction in cytokine (TNF-a) and Crp gene expression, increase in glutathione, reduction in ROS production, and increase in uremic toxin excretion, and exhibits excellent effects in preventing liver damage and improving liver function by means of inhibition of NO production, reduction in cytokine (IL6) and MCP1 and CXCL1 gene expression, increase in glutathione, suppression of expression of fibrosis markers (ACTA2, Vim, COL3A1) of hepatic stellate cells, restoration of GSH in liver tissue, increase in antioxidant enzyme activity, and suppression of expression of antiinflammatory- and antifibrotic-related genes and proteins, and thus, the complex is applicable as a pharmaceutical composition for preventing or treating kidney and / or liver diseases, and as a health functional food and food composition for preventing or ameliorating liver diseases.

The present application provides a peony seed meal extract, an extraction method and application, and belongs to the technical field of medicine. The extraction method comprises the following steps: after defatting treatment of peony seed meal, methanol solution is used for extraction to prepare a crude extract; gradient elution is performed on the crude extract, in the gradient elution process, an ethanol aqueous solution with a flow rate of 5-15 mL / min and a volume concentration of 8-12%, 18-22%, 28-32%, 38-42%, 48-52%, 58-62%, 68-72% and 78-82% is used for gradient elution, each concentration elution is performed for 4-6 column volumes, and the elution product of the ethanol aqueous solution with a volume concentration of 48%-72% is collected. The total flavone purity of the peony seed meal extract can reach more than 90%. The extract plays an obvious anti-fibrosis role by inhibiting the activation of hepatic stellate cells, and in vivo experiments show that it can significantly improve the liver function indexes of CCl4-induced liver fibrosis mice, and reduce the pathological damage and collagen deposition of active substances in liver tissue.